Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.

The regulation of toll-like receptor (TLR) signaling in a tumor microenvironment is poorly understood despite its importance in cancer biology. To address this problem, TLR7-responses of chronic lymphocytic leukemia (CLL) cells were studied in the presence and absence of a human stromal cell-line derived from a leukemic spleen. CLL cells alone produced high levels of tumor necrosis factor (TNF)-α and proliferated in response to TLR7-agonists. A signal transducer and activator of transcription 3 -activating stromal factor, identified as interleukin (IL)-6, was found to upregulate microRNA (miR)-17 and miR-19a, target TLR7 and TNFA messenger RNA, and induce a state of tolerance to TLR7-agonists in CLL cells. Overexpression of the miR-17-92 cluster tolerized CLL cells directly and miR-17 and miR-19a antagomiRs restored TLR7-signaling. Inhibition of IL-6 signaling with antibodies or small-molecule Janus kinase inhibitors reversed tolerization and increased TLR7-stimulated CLL cell numbers in vitro and in NOD-SCIDγc (null) mice. These results suggest IL-6 can act as tumor suppressor in CLL by inhibiting TLR-signaling.

[1]  Johannes Zuber,et al.  Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis , 2015, Nature Communications.

[2]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[3]  E. Giné,et al.  Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. , 2014, Blood.

[4]  Andrew Hopkinson,et al.  Concise Review: Evidence for CD34 as a Common Marker for Diverse Progenitors , 2014, Stem cells.

[5]  L. Partridge,et al.  Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin , 2014, Nature Immunology.

[6]  B. Cullen,et al.  MicroRNA‐17∼92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways , 2013, The EMBO journal.

[7]  M. Minden,et al.  PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. , 2013, Blood.

[8]  W. Hung,et al.  STAT3 upregulates miR-92a to inhibit RECK expression and to promote invasiveness of lung cancer cells , 2013, British Journal of Cancer.

[9]  C. Heirman,et al.  Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy , 2013, Gene Therapy.

[10]  Adrian Wiestner,et al.  Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  V. Gattei,et al.  TLR9 signaling defines distinct prognostic subsets in CLL. , 2013, Frontiers in bioscience.

[12]  Stavroula Ntoufa,et al.  Distinct Innate Immunity Pathways to Activation and Tolerance in Subgroups of Chronic Lymphocytic Leukemia with Distinct Immunoglobulin Receptors , 2012, Molecular medicine.

[13]  D. Spaner,et al.  Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. , 2012, Cancer research.

[14]  J. Arthur,et al.  Inhibition of JAKs in Macrophages Increases Lipopolysaccharide-Induced Cytokine Production by Blocking IL-10–Mediated Feedback , 2012, The Journal of Immunology.

[15]  C. Fegan,et al.  Mimicking the tumour microenvironment: three different co‐culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells , 2012, British journal of haematology.

[16]  M. R. Hough,et al.  The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. , 2012, Blood.

[17]  Jing Li,et al.  Abstract 4931: Biomarker discovery in a large panel of cell lines shows different sample size requirement for prediction of response across a set of compounds , 2012 .

[18]  S. Gibson,et al.  Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia , 2012, Leukemia & lymphoma.

[19]  J. Bromberg,et al.  Targeting the interleukin-6/Jak/stat pathway in human malignancies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Volinia,et al.  The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes , 2012, Leukemia.

[21]  J. Burger.  Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. , 2011, Hematology. American Society of Hematology. Education Program.

[22]  Wentian Li,et al.  Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells , 2011, Molecular medicine.

[23]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[24]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[25]  J. Minna,et al.  STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. , 2011, Cancer research.

[26]  D. Spaner,et al.  Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. , 2011, Blood.

[27]  Richard Sherry,et al.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. , 2011, Blood.

[28]  N. Kay,et al.  Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. , 2010, Blood.

[29]  Harvey Herschman,et al.  B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia , 2010, Proceedings of the National Academy of Sciences.

[30]  Y. Shi,et al.  A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia , 2010, Leukemia.

[31]  Y. Shi,et al.  Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells , 2009, Clinical and experimental immunology.

[32]  G Brockhoff,et al.  Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles , 2009, Leukemia.

[33]  R. Speich,et al.  Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3–microRNA Cluster 17/92 Pathway , 2009, Circulation research.

[34]  Paolo Ghia,et al.  Expression and function of toll like receptors in chronic lymphocytic leukaemia cells , 2009, British journal of haematology.

[35]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[36]  J. Mendell.  miRiad Roles for the miR-17-92 Cluster in Development and Disease , 2008, Cell.

[37]  D. Spaner,et al.  Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. , 2007, Cancer research.

[38]  D. Spaner,et al.  Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia , 2007, Leukemia.

[39]  D. Spaner,et al.  Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity1 , 2006, The Journal of Immunology.

[40]  Y. Shi,et al.  Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells , 2006, Leukemia.

[41]  D. Spaner,et al.  Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod , 2005, Leukemia & lymphoma.

[42]  J. Cook,et al.  Review: Molecular mechanisms of endotoxin tolerance , 2004 .

[43]  J. Cook,et al.  Molecular mechanisms of endotoxin tolerance. , 2004, Journal of endotoxin research.

[44]  K. Raju,et al.  A role for perforin in activation-induced cell death. , 1998, Journal of immunology.

[45]  D. Wallach,et al.  Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta , 1993 .

[46]  D. Wallach,et al.  Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. , 1993, Blood.